Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 23, Issue 10, Pages -Publisher
MDPI
DOI: 10.3390/ijms23105396
Keywords
glioblastoma; immunotherapy; dendritic cells; CD4+T cells; vaccine; cancer treatment
Funding
- Fundacao Faculdade de Medicina, Universidade de Sao Paulo, Brazil
- Sao Paulo Research Foundation-FAPESP [2014/25988-1, 2016/01137-8]
- Coordination for the Improvement of Higher Education Personnel-CAPES
- National Council for Scientific and Technological Development-CNPq [409825/2016-6]
- CNPq [308053/2017-6]
Ask authors/readers for more resources
This case study investigated the treatment of glioblastoma in a 25-year-old female patient with a dendritic-tumor cell fusion vaccine. The findings suggest that tumor-specific CD4+ T-cell numbers and phenotype could serve as biomarkers for treatment efficacy.
Immunotherapy has brought hope to the fight against glioblastoma, but its efficacy remains unclear. We present the case of CST, a 25-year-old female patient with a large right-hemisphere glioblastoma treated with a dendritic-tumor cell fusion vaccine. CST showed a near-complete tumor response, with a marked improvement in her functional status and simultaneous increases in tumor-specific CD8+ and CD4+ T cells. Two months before recurrence, the frequency of tumor-specific T cells decreased, while that of IL-17 and CD4+ T cells increased. CST passed away 15 months after enrollment. In this illustrative case, the tumor-specific CD4+ T-cell numbers and phenotype behaved as treatment efficacy biomarkers, highlighting the key role of the latter in glioblastoma immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available